Heidelberg ImmunoTherapeutics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Clinical Trials
7
Active:1
Completed:5
Trial Phases
3 Phases
Phase 1:1
Phase 2:2
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Not Applicable
3 (50.0%)Phase 2
2 (33.3%)Phase 1
1 (16.7%)Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
Phase 2
Terminated
- Conditions
- Herpes Labialis
- Interventions
- Drug: HDIT101 (blinded therapy)Drug: Placebo (blinded therapy)Behavioral: Photo documentation of orolabial herpes lesionsBehavioral: Completion of questionnaires (patient-reported outcomes)Procedure: 28-day swabbing of orolabial regionProcedure: Blood drawings
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Heidelberg ImmunoTherapeutics GmbH
- Target Recruit Count
- 761
- Registration Number
- NCT04539483
- Locations
- 🇩🇪
emovis GmbH, Berlin, Germany
🇩🇪Infektio Research GmbH & Co. KG, Frankfurt am Main, Germany
🇩🇪bioskin Prüfzentrum, Hamburg, Germany
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection
Phase 2
Completed
- Conditions
- Herpes Genitalis
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Heidelberg ImmunoTherapeutics GmbH
- Target Recruit Count
- 122
- Registration Number
- NCT04165122
- Locations
- 🇩🇪
emovis GmbH, Berlin, Germany
🇩🇪Praxis Jessen2+Kollegen, Berlin, Germany
🇩🇪WIR "Walk In Ruhr" im St. Elisabeth Hospital, Bochum, Germany
News
No news found